CORE Biomedicine Scores $21M Series A

CORE Biomedicine has closed a $21 million Series A round led by UTokyo Innovation Platform and Elikon Venture, with multiple other investors joining.

The Boston biotech will use the funding to advance its lineage-based precision oncology platform.

Its approach aims to develop cancer therapies by targeting core biological pathways, not just genomics, potentially broadening the pool of drug targets and patients.